Investing.com -- Eli Lilly and Company (NYSE:LLY) shares trended higher after the drug maker said regulators had approved its Jardiance Type 2 diabetes treatment for children aged 10 and up.
Shares rose 0.2% and are up 23.9% so far this year.
The Food and Drug Administration approved the use after a study showed patients age 10 to 17 achieved lower blood sugar levels than with a placebo. The approval was for Jardiance and Synjardy, for Eli Lilly and its partner Boehringer Ingelheim.
The approvals give more options for oral drug treatments. Metformin, the only other oral drug available for the treatment of children with type 2 diabetes, was initially approved for pediatric use in 2000. Jardiance and Synjardy were approved by the FDA in 2014 and 2015, respectively, to treat Type 2 diabetes in adults.
UBS and BofA Securities recently raised their ratings on Lilly stock to buy. Analysts are awaiting details about Lilly's hotly anticipated Mounjaro, one of a new group of Type 2 diabetes drugs that have been shown to be effective in fighting obesity. Executives are expected to talk about Mounjaro at this weekend's American Diabetes Association conference.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.